Ngo mentions that availability of Wegovy could be difficult because the drug is so popular. “Supply chain issues may arise from time to time. Novo Nordisk is actively working to ramp up ...

positive signals' emerge around future supply of GLP-1 drugs Lilly has been steadily chipping away at Novo’s dominance in the ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Co-pays for weight loss drugs Wegovy and Zepbound are skyrocketing. FDA warns of fake Ozempic in US drug supply chain The controversy comes at a time when some 40% of the American public are obese ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...

According to NovoCare, Wegovy’s manufacturer, people with private or commercial insurance can pay as little as $0 per 28-day supply of the medication. People without insurance can expect to pay ...